Clinical trial Recruiting at 1 site Observational Ages 18 and up

Registry of long-term antithrombotic therapy for atrial fibrillation

Official title: Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation

Run by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · NCT04347187 · Data updated 2026-11-12

This study looks at how safe and effective long-term blood-thinning treatments are for people with atrial fibrillation by tracking any complications they might have.

More Atrial Fibrillation trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Government
Locations1 site (Moscow)
StatusRecruiting
StartedJanuary 15, 2015
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedMay 1, 2026
Trial IDNCT04347187 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with documented atrial fibrillation and a CHA2DS2VASC score greater than 1.

Probably not a fit

Patients who are unwilling or unable to provide informed consent or have severe comorbid conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the rates of ischemic and hemorrhagic complications associated with long-term antithrombotic therapy in patients diagnosed with atrial fibrillation. Conducted at a single center in Russia, the study will involve patients who meet specific criteria for antithrombotic treatment. By documenting outcomes over time, the study seeks to provide insights into the safety and efficacy of anticoagulants in this patient population.

Why it matters

Potential benefit: If successful, this study could enhance understanding of the risks associated with long-term antithrombotic therapy, potentially leading to improved treatment strategies for patients with atrial fibrillation.

How similar studies have gone: Other studies have explored antithrombotic therapy in atrial fibrillation, indicating that this approach has been previously tested, though the specific focus on long-term outcomes in this registry may provide novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Documented atrial fibrillation with CHA2DS2VASC \> 1

Exclusion Criteria:

* Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

Where it's running

  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
    Moscow, Russia
    Recruiting

Study contacts

  • Principal investigator: Elizaveta Panchenko, PhD — National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
  • Study coordinator: Ekaterina Kropacheva, PhD
  • Email: katekrab@list.ru
  • Phone: +79166760695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.